DS
CRSP icon

David Shaw’s CRISPR Therapeutics CRSP Stock Holding History

David Shaw’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9M Sell
108,200
-34,500
-24% -$1.82M ﹤0.01% 2266
2026
Q1 		$6.79M Sell
142,700
-238,400
-63% -$12.6M ﹤0.01% 1951
2025
Q4 		$20M Buy
381,100
+20,800
+6% +$1.25M 0.01% 1243
2025
Q3 		$23.4M Buy
360,300
+226,700
+170% +$13M 0.01% 1077
2025
Q2 		$6.5M Buy
133,600
+82,200
+160% +$3.18M ﹤0.01% 1825
2025
Q1 		$1.75M Sell
51,400
-23,500
-31% -$996K ﹤0.01% 2708
2024
Q4 		$2.95M Buy
74,900
+15,600
+26% +$737K ﹤0.01% 2411
2024
Q3 		$2.79M Sell
59,300
-7,300
-11% -$370K ﹤0.01% 2438
2024
Q2 		$3.6M Sell
66,600
-151,900
-70% -$8.79M ﹤0.01% 2112
2024
Q1 		$14.9M Buy
218,500
+57,600
+36% +$4.12M 0.01% 1109
2023
Q4 		$10.1M Buy
160,900
+68,400
+74% +$3.78M 0.01% 1361
2023
Q3 		$4.2M Hold
92,500
– – ﹤0.01% 1956
2023
Q2 		$5.19M Sell
92,500
-18,000
-16% -$1.02M 0.01% 1836
2023
Q1 		$5M Sell
110,500
-37,900
-26% -$1.84M 0.01% 1938
2022
Q4 		$6.03M Buy
148,400
+32,500
+28% +$1.72M 0.01% 1912
2022
Q3 		$7.57M Hold
115,900
– – 0.01% 1618
2022
Q2 		$7.04M Buy
115,900
+48,000
+71% +$2.82M 0.01% 1748
2022
Q1 		$4.26M Sell
67,900
-2,000
-3% -$126K ﹤0.01% 2506
2021
Q4 		$5.3M Buy
69,900
+19,900
+40% +$1.74M ﹤0.01% 2307
2021
Q3 		$5.6M Buy
50,000
+10,000
+25% +$1.26M 0.01% 2003
2021
Q2 		$6.48M Buy
40,000
+30,000
+300% +$3.65M 0.01% 1838
2021
Q1 		$1.22M Sell
10,000
-10,000
-50% -$1.51M ﹤0.01% 2965
2020
Q4 		$3.06M Buy
20,000
+10,000
+100% +$1.18M ﹤0.01% 2254
2020
Q3 		$836K Hold
10,000
– – ﹤0.01% 2963
2020
Q2 		$735K Hold
10,000
– – ﹤0.01% 3132
2020
Q1 		$424K Hold
10,000
– – ﹤0.01% 3288
2019
Q4 		$609K Buy
+10,000
New +$546K ﹤0.01% 3289

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's CRSP Position: Q2 2026 in Review

David Shaw opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 893,812 shares worth $48.7M. The stake represents 0.02% of the portfolio and ranks #774 among its holdings. This is a return to the name: David Shaw previously reported a position in CRSP as recently as Q3 2024.

David Shaw first reported a position in CRSP in Q1 2018 and has held it in 24 quarters since. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • David Shaw held 893,812 shares of CRISPR Therapeutics worth $48.7M as of Q2 2026.
  • CRISPR Therapeutics was a new David Shaw position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of David Shaw's portfolio in Q2 2026, its #774 holding.
  • David Shaw first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.